Molecular Profile of Barrett’s Esophagus and Gastroesophageal Reflux Disease in the Development of Translational Physiological and Pharmacological Studies

• Main Authors: Edyta Korbut, Vincent T Janmaat, Mateusz Wierdak, Jerzy Hankus, Dagmara Wójcik, Marcin Surmiak, Katarzyna Magierowska, Tomasz Brzozowski, Maikel P Peppelenbosch, Marcin Magierowski
• Format: Article
• Language: English
• Published: MDPI AG 2020-09-01
• Series: International Journal of Molecular Sciences
• Subjects: Barrett’s esophagus; esophageal epithelium; molecular profile; molecular gastrointestinal pharmacology; molecular gastrointestinal pathophysiology
• Online Access: https://www.mdpi.com/1422-0067/21/17/6436
• ISSN: 1661-6596; 1422-0067

Barrett’s esophagus (BE) is a premalignant condition caused by gastroesophageal reflux disease (GERD), where physiological squamous epithelium is replaced by columnar epithelium. Several in vivo and in vitro BE models were developed with questionable translational relevance when implemented separately. Therefore, we aimed to screen Gene Expression Omnibus 2R (GEO2R) databases to establish whether clinical BE molecular profile was comparable with animal and optimized human esophageal squamous cell lines-based in vitro models. The GEO2R tool and selected databases were used to establish human BE molecular profile. BE-specific mRNAs in human esophageal cell lines (Het-1A and EPC2) were determined after one, three and/or six-day treatment with acidified medium (pH 5.0) and/or 50 and 100 µM bile mixture (BM). Wistar rats underwent microsurgical procedures to generate esophagogastroduodenal anastomosis (EGDA) leading to BE. BE-specific genes (keratin (<i>KRT)1</i>, <i>KRT4</i>, <i>KRT5</i>, <i>KRT6</i>A, <i>KRT13</i>, <i>KRT14</i>, <i>KRT15</i>, <i>KRT16</i>, <i>KRT23</i>, KRT24, <i>KRT7</i>, <i>KRT8</i>, <i>KRT18</i>, <i>KRT20</i>, trefoil factor (<i>TFF</i>)<i>1</i>, <i>TFF2</i>, <i>TFF3</i>, villin (<i>VIL</i>)<i>1</i>, mucin (<i>MUC</i>)<i>2</i>, <i>MUC3A/B</i>, <i>MUC5B</i>, <i>MUC6</i> and <i>MUC13</i>) mRNA expression was assessed by real-time PCR. Pro/anti-inflammatory factors (interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, tumor necrosis factor α, interferon γ, granulocyte-macrophage colony-stimulating factor) serum concentration was assessed by a Luminex assay. Expression profile in vivo reflected about 45% of clinical BE with accompanied inflammatory response. Six-day treatment with 100 µM BM (pH 5.0) altered gene expression in vitro reflecting in 73% human BE profile and making this the most reliable in vitro tool taking into account two tested cell lines. Our optimized and established combined in vitro and in vivo BE models can improve further physiological and pharmacological studies testing pathomechanisms and novel therapeutic targets of this disorder.